Speakers at the Portfolio Private Health Forum 2026 argued that introducing a Care Quality Commission (CQC)–style regulator in Hungary could fundamentally reshape the private healthcare market by shifting incentives toward prevention, transparency and measurable quality improvements. Toli Onon, Chief Inspector of Hospitals at the Care Quality Commission in the United Kingdom, outlined the UK regulatory framework. Attila Végh, CEO of QuantumDoctor.hu, discussed the practical implications for Hungary as officials prepare legislation for a new national quality authority.
What the CQC model involves
The CQC is an independent regulator for health and social care in the UK: it registers, inspects and rates NHS and private hospitals, GP practices and social care providers to ensure safe and effective care. Ratings are published on a four-point scale: outstanding, good, requires improvement and inadequate.
Onon emphasized that regulation is intended to deliver tangible improvements in patient care rather than just inspections. The CQC uses two complementary sets of tools:
- Hard levers: tightly controlled market entry (registration requirements), civil and criminal sanctions, formal warnings to providers and, ultimately, revocation of operating licences.
- Soft levers: public ratings, information to help patient choice, incentives for learning from peers and dissemination of best practices.
How oversight affects providers
According to the UK experience, regulation influences providers through multiple channels. The anticipatory effect is particularly strong: providers often remediate deficits before inspectors arrive. The informational effect of published data also pressures management to act quickly. The CQC assesses every registered provider against five core questions: is care Safe, Effective, Caring, Responsive to people’s needs and Well-led. These dimensions are measured via extensive data collection, patient and staff feedback, complaints and partner signals, unannounced site visits and rigorous clinical audits.
Market-shaping power of ratings
Public CQC ratings have market consequences: they are now an integral part of mergers and acquisitions due diligence. A rating of outstanding or good increases buyer confidence and strengthens negotiating positions, while requires improvement or inadequate ratings can force large price discounts or scuttle transactions. Végh stressed that similar dynamics in Hungary could materially affect investors and the valuation of private hospitals.
Digitization and prevention as prerequisites
Onon argued that digitizing analogue processes and prioritizing prevention are essential for a successful transition. Digital tools can substantially improve patient safety but introduce risks as well: algorithmic errors may produce misdiagnoses, data breaches or subtle delivery failures, and technology can exacerbate access inequalities. Public education will be necessary to build trust in new tools.
A cited British survey of 2,000 primary-care patients underlined public concerns:
- 83% fear that deployed artificial intelligence could make diagnostic or treatment errors;
- 82% worry healthcare staff will rely too much on technology instead of their own expertise;
- 81% fear losing the human doctor–patient relationship;
- 69% reported data protection and cybersecurity concerns.
Végh noted that these perceptions imply a need for substantial education and risk management.
Hungarian plans: EMH from 1 January 2027
Hungarian authorities are developing the legal framework for an independent, ministry‑separate Health Quality Oversight Authority (Egészségügyi Minőségellenőrzési Hatóság, EMH) modeled on the CQC, planned to start operating on 1 January 2027. The EMH would impose a unified quality assurance regime on both public and private providers. Conference speakers argued this could trigger market reconfiguration, improve patient safety and change how providers are priced and purchased.
Information asymmetry and three enforcement models
Végh highlighted information asymmetry as a major issue on the Hungarian private market: patients often lack objective, measurable data on the quality and safety of care. The conference contrasted three international approaches to enforce quality:
- Independent accreditation (for example, Joint Commission International) — strong safety requirements but voluntary and costly.
- Payer-driven control — where payers enforce outcomes, for example by linking full payment to successful rehabilitation after procedures.
- National regulatory authority (CQC-style) — mandatory registration, unannounced inspections and public ratings across defined quality domains.
A cautionary example: rapid recovery after failure
Végh illustrated the power of independent oversight with a personal case: in 2011, while leading the Cambridge University Hospitals group (90 sites, 4,000 staff), the organisation was rated “Inadequate.” Initial legal challenges gave way to rapid organisational change after CQC’s ultimatum. Within a month the leadership involved all staff in addressing systemic issues, and within 18 months the hospital moved into the top decile for the measured indicators — one of the fastest turnarounds in English health‑care history.
Conclusion
Speakers concluded that the greatest value of a CQC-like system lies not in the label but in independent scrutiny, public transparency and enforceable change. With plans for an EMH due to start on 1 January 2027, Hungary appears set to adopt a regulatory regime that will influence patient safety, provider behaviour and the commercial valuation of health-care organisations.
Participants and discussion
Following the presentations, an interactive discussion between Attila Végh and Toli Onon covered operational consequences for a future authority. Audience questions came from participants including Kiss András (BEK), Fendler Judit (University of Szeged) and Kincses Gyula (former MOK president).
